立方制药(003020) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥628,617,238.94, representing a 14.48% increase compared to ¥549,093,775.22 in the same period last year[3] - Net profit attributable to shareholders was ¥47,126,894.93, up 13.04% from ¥41,691,278.46 year-on-year[3] - Total operating revenue for Q1 2022 was CNY 628,617,238.94, an increase of 14.5% compared to CNY 549,093,775.22 in the same period last year[23] - Net profit for Q1 2022 reached CNY 47,126,894.93, representing a 13.0% increase from CNY 41,691,278.46 in Q1 2021[24] - Basic and diluted earnings per share for Q1 2022 were both CNY 0.51, compared to CNY 0.45 in the same period last year[25] Cash Flow and Liquidity - The net cash flow from operating activities increased by 90.76% to ¥14,015,957.65, compared to ¥7,347,550.03 in Q1 2021[3] - The net cash flow from financing activities was -3,094,585.68, compared to -4,599,124.38 in the previous period, indicating an improvement of approximately 32.7%[29] - The net increase in cash and cash equivalents for the period was -480,845,312.40, compared to -592,230,291.32 in the previous period, reflecting a reduction of about 18.8%[29] - The company's cash and cash equivalents decreased to RMB 180,099,316.29 from RMB 654,253,951.34, representing a decline of about 72.5%[18] - The company’s cash and cash equivalents decreased by approximately 83.6% from the beginning to the end of the period[29] Assets and Liabilities - Total assets at the end of Q1 2022 reached ¥1,899,968,983.75, a 13.47% increase from ¥1,674,444,924.99 at the end of the previous year[3] - The total current liabilities increased to RMB 508,970,681.33 from RMB 328,053,931.54, which is an increase of about 55%[20] - The total liabilities at the end of Q1 2022 were CNY 548,931,318.07, up from CNY 370,534,154.24 at the beginning of the year[21] - The total equity attributable to shareholders of the parent company was CNY 1,351,037,665.68, an increase from CNY 1,303,910,770.75 at the start of the year[21] - The company reported a total non-current asset value of RMB 474,764,515.58, up from RMB 454,797,205.98 at the beginning of the year, reflecting an increase of approximately 4.5%[19] Operational Metrics - Accounts receivable increased by 46.97% to ¥415,430,214.90, primarily due to new sales and unexpired credit terms with downstream customers[8] - Inventory levels rose by 44.89% to ¥273,628,907.68, attributed to normal stockpiling in the pharmaceutical business[8] - Research and development expenses for Q1 2022 totaled CNY 13,199,412.15, slightly up from CNY 12,404,825.37 in Q1 2021[24] - Sales expenses increased to CNY 162,523,573.63 in Q1 2022, compared to CNY 143,103,211.68 in the previous year[24] Government Support and Equity - The company received government subsidies amounting to ¥2,610,896.60, which is a 328.92% increase compared to ¥608,718.15 in Q1 2021[10] - The company plans to transfer 4.9383% equity in Minoway for RMB 32,098,800, pending completion of regulatory filings[16] - The company holds a 12.3457% stake in Nanjing Minoway Pharmaceutical Technology Co., Ltd. as of January 21, 2022[15] Reporting and Audit - The first quarter report was not audited, which may affect the reliability of the financial data presented[30] - The report was issued by the board of directors on April 29, 2022, indicating the timeliness of the financial disclosure[31]